Search
- May 20
ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF
John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than...
- Apr 26
John Hood on Endeavor's $132.5M series C and hedgehog inhibition for IPF
He describes the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise.
.png){kind=logo}
.png){kind=logo}